Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

Ferreiro-Pantín, M.; Herranz, Urbano Anido; Betancor, Yoel Z.; Cebey-López, Victor; León‐Mateos, Luis; García‐González, Jorge; García-Acuña, S.M.; Fernández-Díaz, Natalia; Tubío, José M. C.; López‐López, Rafael; Ruíz-Bañobre, Juan

doi:10.1016/j.esmoop.2023.101611

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most informative tissue-based biomarkers is the recently described gene expression Immunotherapy Response Score (IRS), which integrates TMB and the expression of the PD-1, PD-L1, TOP2A, and ADAM12 genes [18]. IRS has been assessed as informative in a post hoc analysis of the phase 2 IMvigor210 trial, with an mOS of 16.46 months vs. 7.43 months for the IRS-high vs. IRS-low patients, respectively (p < 0.001) [19].…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors

Mokbel,

Baciarello,

Lavaud

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free survival (PFS) in a development (D, n = 264) and a validation (V, n = 132) cohort of platinum-pretreated a/mUC pts receiving ICIs at L2 or further line. A nomogram and inflammatory prognostic index (U-IPI) were developed. The index was also tested in a control cohort of patients treated with chemotherapy only (C, n = 114). Results: The strongest predictors of OS were baseline platelet/lymphocyte (PLR) and neutrophil/lymphocyte (NLR) ratios, and lactate dehydrogenase (LDH), NLR, and albumin changes at 4 weeks. These were used to build the U-IPI, which can distinctly classify patients into good or poor response groups. The nomogram scoring is significant for PFS and OS (p < 0.001 in the D, V, and combined cohorts) for the immunotherapy (IO) cohort, but not for the control cohort. Conclusions: The lack of a baseline systemic inflammatory profile and the absence of early serum inflammatory biomarker changes are associated with significantly better outcomes on ICIs in a/mUC pts. The U-IPI is an easily applicable dynamic prognostic tool for PFS and OS, allowing for the early identification of a sub-group with dismal outcomes that would not benefit from ICIs, while distinguishing another that draws an important benefit.

show abstract

Section: Introductionmentioning

confidence: 99%